1⃣New definition:
📌Same mPAP threshold as Nice 2018 (mPAP> 20 mmHg)
📌Lower PVR threshold (PVR >2 WU)! 👈
📌No more DPG to differentiate Ipc & Cpc
📌Re-introduction of #ExercisePH in definition!👈
(2/10)
2⃣Diagnostic algorithm:
📌Fast track for referral to a #PH centre at any point of warning signs or #PAH or #CTEPH suspected
📌Individualised route for suspected #LungDisease but rapid cross-referral if necessary
📌If eventually PAH/CTEPH suspected, follow to tables 😵💫
(3/10)
3⃣Risk stratification:
📌3-strata: fundamentally similar to previous ➡️to be used at initial evaluation
📌4-strata: identifies intermediate-low & intermediate-high categories ➡️to be used at follow-up
(4/10)
4⃣New #treatment algorithm (1/2):
📌3-strata risk assessment for initial evaluation, but 4-strata risk for follow up 🤔
👉At initial evaluation:
📌Only patients with 🫀or🫁comorbidities (any risk) ➡️initial monotherapy
📌Low-interm risk w/out comorb ➡️PDE5i + ERAs
(5/10)
5⃣Definition of a PH centre:
📌Skills & facilities required in a PH specialist centre
📌Definition of the processes involved for the care of #PH patients
📌Recommendation to connect w #PatientAssociation!
🎯Focus on the structure of care ensures appropriate management👈
(7/10)
6⃣Many other new changes in specific settings:
📌CTEPH treatment w BPA mostly after medical therapy in inoperable pts
📌New classification of hemodynamic severity in Group 3 PH: PVR>5 WU! 👈
📌More detailed recommendations for the management of vasodilator tests & CCB+ pts
(8/10)
7⃣In general, the new guidelines are a trove of useful insights into physiopathology, guidance in >> detail than previous documents, tables & fantastic images, which obviously took a lot of work!
It will take a while to digest all this 😅
The visual style greatly helps!
(9/10)